D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

D. Boral Capital reiterated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research report released on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.

RVPH has been the topic of several other research reports. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Roth Mkm started coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective on the stock. EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Finally, Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Buy” and an average price target of $11.40.

Reviva Pharmaceuticals Stock Down 2.6 %

Shares of RVPH opened at $1.89 on Tuesday. The firm has a market capitalization of $63.20 million, a PE ratio of -1.70 and a beta of -0.12. The firm has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.33. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 17.9% during the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after buying an additional 42,376 shares in the last quarter. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, EMC Capital Management lifted its position in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after acquiring an additional 26,134 shares in the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.